mRNA COVID-19 Vaccines Not Tied to Increases in Guillain-Barré Syndrome
However, the Janssen COVID-19 vaccine was associated with increased risk at 21 and 42 days postvaccination
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.